MANEVeradermics, Incvs its industry peers
A metric-by-metric comparison of Veradermics, Inc against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MANE본 종목 | $5.8B#5 | — | 7.2x#3 | — | — | -164.3%#6 | — | -8.6%#3 | — | — | — | — |
| ALKS | $7.6B#1 | 119.3x#1 | 4.2x#1 | 5.2x#1 | -5.2%#3 | -34.2%#5 | 17.2%#1 | 13.4%#1 | 7.5%#1 | — | 47.1%#1 | — |
| IONS | $7.2B#2 | — | 16.4x#5 | 7.7x#2 | 33.8%#2 | 16.0%#3 | -40.4%#2 | -86.7%#6 | -20.6%#2 | — | -41.4%#2 | — |
| ORKA | $6.4B#3 | — | 5.8x#2 | — | — | -25.9%#4 | — | -9.5%#4 | — | — | — | — |
| RYTM | $6.4B#4 | — | 61.8x#6 | 33.5x#3 | 45.8%#1 | 24.6%#1 | -101.2%#3 | -0.2%#2 | -133.8%#3 | — | — | — |
| ERAS | $5.0B#6 | — | 13.9x#4 | — | — | 23.0%#2 | — | -34.4%#5 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-11-02.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice